rs104894368
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1PM2
The ENST00000228841.15(MYL2):c.64G>T(p.Glu22Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,100 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
MYL2
ENST00000228841.15 stop_gained
ENST00000228841.15 stop_gained
Scores
4
2
1
Clinical Significance
Conservation
PhyloP100: 7.53
Genes affected
MYL2 (HGNC:7583): (myosin light chain 2) This gene encodes a major sarcomeric protein in mammalian striated muscle. The encoded protein plays a role in embryonic heart muscle structure and function, while phosphorylation of the encoded protein is involved in cardiac myosin cycling kinetics, torsion and function in adults. Mutations in this gene are associated with hypertrophic cardiomyopathy 10 and infant-onset myopathy. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 51 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL2 | NM_000432.4 | c.64G>T | p.Glu22Ter | stop_gained | 2/7 | ENST00000228841.15 | NP_000423.2 | |
MYL2 | NM_001406745.1 | c.64G>T | p.Glu22Ter | stop_gained | 2/6 | NP_001393674.1 | ||
MYL2 | NM_001406916.1 | c.7G>T | p.Glu3Ter | stop_gained | 2/7 | NP_001393845.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYL2 | ENST00000228841.15 | c.64G>T | p.Glu22Ter | stop_gained | 2/7 | 1 | NM_000432.4 | ENSP00000228841 | P1 | |
MYL2 | ENST00000548438.1 | c.64G>T | p.Glu22Ter | stop_gained | 2/6 | 3 | ENSP00000447154 | |||
MYL2 | ENST00000663220.1 | c.7G>T | p.Glu3Ter | stop_gained | 2/7 | ENSP00000499568 | ||||
MYL2 | ENST00000546404.1 | c.64G>T | p.Glu22Ter | stop_gained | 2/2 | 2 | ENSP00000499645 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152100Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152100
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251472Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135908
GnomAD3 exomes
AF:
AC:
1
AN:
251472
Hom.:
AF XY:
AC XY:
0
AN XY:
135908
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1461712Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 727142
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1461712
Hom.:
Cov.:
30
AF XY:
AC XY:
0
AN XY:
727142
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152100Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74294
GnomAD4 genome
AF:
AC:
1
AN:
152100
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74294
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 05, 2014 | p.Glu22Stop (GAA>TAA): c.64 G>T in exon 2 of the MYL2 gene (NM_000432.3). The Glu22Stop mutation in the MYL2 gene has been reported in one individual who was part of the Framingham and Jackson Heart Study cohort (Bick et al., 2012). This individual had left ventricular wall thickness that measured within in the normal range (Bick et al., 2012). Glu22 stop may cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. However, no other nonsense mutations in the MYL2 gene have been reported in association with HCM. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in HCM panel(s). - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 01, 2022 | The p.E22* variant (also known as c.64G>T), located in coding exon 2 of the MYL2 gene, results from a G to T substitution at nucleotide position 64. This changes the amino acid from a glutamic acid to a stop codon within coding exon 2. The predicted stop codon occurs in the 5’ end of theMYL2 gene. Premature termination codons in the 5’ end of a gene have been reported to escape nonsense-mediated mRNAdecay and/or lead to re-initiation (Rivas et al. Science. 2015 May 8;348(6235):666-9; Lindeboom et al. Nat Genet. 2016 Oct;48(10):1112-8; Rhee et al. Sci Rep. 2017 May 10;7(1):1653). Direct evidence for this alteration is unavailable, however premature termination codons are typically deleterious in nature. This variant has been reported in one participant from the Jackson Heart Study cohort, whose echocardiogram values were not indicative of cardiac disease at the time of evaluation (Bick AG et al. Am J Hum Genet, 2012 Sep;91:513-9). Although biallelic loss of function alterations in MYL2 have been associated with autosomal recessive MYL2-related myofibrillar myopathy with cardiomyopathy, haploinsufficiency for MYL2 has not been clearly established as a mechanism of disease for autosomal dominant MYL2-related cardiomyopathy. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at